Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This research study is for people in the UK who have mantle cell lymphoma (MCL), a type of blood cancer. We are looking into a new medicine called pirtobrutinib. This drug works in a similar way to other treatments already approved by health bodies. The main aim is to see how pirtobrutinib compares to these existing medicines (like ibrutinib, acalabrutinib, or zanubrutinib) in patients who have already had at least one treatment for their MCL but haven't used this type of drug before. Participants could be in the study for up to two years, or even longer if their cancer doesn't get worse, allowing us to understand the long-term effects of the treatment.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is an important step in finding better ways to treat mantle cell lymphoma (MCL), a type of blood cancer. Many patients with MCL benefit from a group of medicines called BTK inhibitors. These drugs work by blocking a specific protein in cancer cells, which helps to stop the cancer from growing. There are already some approved BTK inhibitors available, and they have helped many people.
This study introduces a new drug called pirtobrutinib (also known as LOXO-305), which is also a BTK inhibitor. We want to see how pirtobrutinib compares to the existing, approved BTK inhibitors. We're particularly interested in patients who have already tried at least one other treatment for their MCL but haven't previously taken a BTK inhibitor. By comparing the new drug with established ones, we hope to learn if pirtobrutinib is a safe and effective new option for these patients.
This is a 'Phase 3' study, which means it's one of the final stages of testing a new medicine before it can potentially be approved for wider use. It's a randomised study, meaning participants will be randomly chosen to receive either pirtobrutinib or one of the existing treatments. This helps us to get reliable results about how well each treatment works. Your participation could help us improve treatment options for people with MCL in the future.
النقاط الرئيسية
- Compares a new drug (pirtobrutinib) to existing approved treatments for MCL.
- For adults with MCL who have had at least one prior treatment.
- A 'Phase 3' study, which is a key step towards potential approval.
- Close medical monitoring and support throughout the study.
- Your participation could help improve future treatments for MCL.
من قد يكون مؤهلاً؟
To join this study, you must have a confirmed diagnosis of mantle cell lymphoma (MCL) and have already received at least one course of treatment for it. Your lymphomamust be measurable, meaning doctors can track its size. You also need to be generally well enough to take part, as assessed by your doctor, and have certain blood test results within a healthy range, including your blood cell counts, liver function, and kidney function.
There are also some reasons why you might not be able to join. For example, if you've already had a BTK inhibitor drug, which is the type of drug being studied, then this trial wouldn't be suitable for you. If you've recently had a stroke or certain types of stem cell or CAR-T cell transplant, or have some serious heart conditions, these would also prevent you from participating. Additionally, certain infections, significant bleeding problems, or issues with absorbing medicines might mean you can't join. Your doctor will carefully review all your health information to see if this study is right for you.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Do I have a confirmed diagnosis of Mantle Cell Lymphoma (MCL)?
- Have I already received at least one prior treatment for my MCL?
- Have I *never* taken a BTK inhibitor drug (like ibrutinib, acalabrutinib, or zanubrutinib) before?
- Am I generally well enough for a clinical trial, based on my doctor's assessment?
- Do I have healthy enough blood counts and organ function (liver, kidney)?
ماذا يتضمن المشاركة؟
If you join this study, it could last for about two years, and possibly longer if the treatment is helping you. You will be randomly assigned to receive either the new drug, pirtobrutinib, or one of the approved BTK inhibitors (ibrutinib, acalabrutinib, or zanubrutinib). You will take the study medication as prescribed by the research team. Throughout the study, you'll have regular hospital visits for check-ups, blood tests, and scans to see how you're responding to the treatment and to monitor your health. These visits will help the medical team track your progress, manage any side effects, and ensure your safety. You'll be closely supported by the study team throughout your involvement.
المخاطر والفوائد المحتملة
Locations (189)
- Alaska Oncology and Hematology, LLCالرمز البريدي المؤكدأنكوريج، الولايات المتحدة
- Arizona Oncology Associates, P.C. - HOPEالرمز البريدي المؤكدفينيكس، الولايات المتحدة
- مركز UCLA الطبيالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- USO-Rocky Mountain Cancer Centerالرمز البريدي المؤكددنفر، الولايات المتحدة
- عيادة مايو في فلوريداالرمز البريدي المؤكدجاكسونفيل، الولايات المتحدة
- Oncology-Hematology Associates of West Browardالرمز البريدي المؤكدتاماراك، الولايات المتحدة
- Florida Cancer Specialists Eastالرمز البريدي المؤكدWest Palm Beach, United States
- University of Kentucky Markey Cancer Centerالرمز البريدي المؤكدLexington, United States
- Mercy Health-Paducah Medical Oncology and Hematologyالرمز البريدي المؤكدبادوكا، الولايات المتحدة
- Tulane Cancer Center Office of Clinical Researchالرمز البريدي المؤكدنيو أورلينز، الولايات المتحدة
- Greenebaum Comprehensive Cancer Centerالرمز البريدي المؤكدبالتيمور، الولايات المتحدة
- DFCI Lymphomaالرمز البريدي المؤكدبوسطن، الولايات المتحدة
أسئلة شائعة
What is Mantle Cell Lymphoma (MCL)?
MCL is a rare type of cancer that affects white blood cells called lymphocytes, which are part of your immune system. It can affect your lymph nodes, spleen, blood, and bone marrow.
What is pirtobrutinib (LOXO-305)?
Pirtobrutinib is an experimental drug designed to treat certain blood cancers, including MCL. It's a 'BTK inhibitor,' meaning it blocks a specific protein in cancer cells to stop them from growing.
ماذا يعني 'المرحلة 3' لدراسة ما؟
Phase 3 is a late stage of clinical research where a new drug is compared to existing treatments or a placebo in a large group of people. This helps confirm its effectiveness and monitor side effects before it can be approved.
هل سأعرف أي علاج سأحصل عليه؟
Yes, this is an 'open-label' study. This means both you and your doctor will know whether you are receiving pirtobrutinib or one of the other approved BTK inhibitor drugs.
كم من الوقت سأكون في الدراسة؟
Participation can last up to two years, and potentially longer if the treatment is working well for you and your cancer doesn't get worse.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.